Clinical Trial Update: Study to Evaluate EB-001 in Reducing Musculoskeletal Pain [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating EB-001 for reducing musculoskeletal pain has completed and posted results in January 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Musculoskeletal Pain

Drugs mentioned

• EB-001

Snippet

Sponsor: Bonti, Inc. | Conditions: Musculoskeletal Pain | Phase 2 | Status: COMPLETED | Results posted: 2019-01-25